HomeAI · summaries
Storia in 5 fonti
FDA approves Viridian eye drug, stoking competition with Amgen's Tepezza
FDA approves Viridian's Lumvoa for thyroid eye disease, launching competition with Amgen's $1.9B Tepezza on efficacy and infusion burden.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Regulatory & Legislative Optometry News
Find the latest Regulatory and Legislative Optometry news articles, videos, podcasts, and meeting coverage from medical experts and key opinion leaders you trust.
- ·
morningstar.com
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
